← Back to all studies
anti-inflammatory foods
Targeting the gut-immune-brain axis: pharmacological insights from depression in inflammatory bowel disease
1 April 2026
Simões Júlia Leão Batista, Braga Geórgia de Carvalho, Assmann Charles Elias, Bagatini Margarete Dulce
Summary
1. Plain-language summary of what the study found: This review highlights that Inflammatory Bowel Disease (IBD) serves as a critical model to understand the deep connection between chronic inflammation and depression. It reveals that an imbalanced gut microbiome in IBD can trigger widespread inflammation, which then impacts the brain and contributes significantly to mental health issues like depression.
2. Key findings:
- There's a strong, bidirectional link between IBD and Major Depressive Disorder, suggesting a shared biological basis rather than just one causing the other.
- Gut dysbiosis (an imbalanced gut microbiome) and a compromised gut barrier are central triggers in IBD, leading to systemic inflammation and subsequently, neuroinflammation.
- This neuroinflammation involves mechanisms like activated brain immune cells (microglia), dysregulation of the stress response (HPA axis), and a metabolic shift that produces neurotoxic compounds instead of mood-boosting serotonin.
- Emerging therapies that target the immune system (like anti-TNF drugs) and the gut microbiome (such as probiotics, psychobiotics, fecal microbiota transplantation, and anti-inflammatory diets) show promise in improving both gut health and depressive symptoms.
3. Practical takeaways for someone interested in nutrition and longevity:
- Prioritize Gut Health for Mind & Body: This research underscores that nourishing your gut through an anti-inflammatory diet, rich in diverse plant fibers and potentially fermented foods, is crucial not just for digestion but also for mental well-being and overall longevity.
- Consider the Gut-Brain Axis: Recognize that your gut health directly impacts your brain. Proactively managing gut health through dietary choices can be a powerful strategy for supporting mood, managing stress, and potentially reducing systemic inflammation, which is a driver of many chronic diseases.
4. Study limitations: The review notes that current literature lacks a precise, quantitative definition for gut dysbiosis and there are limited clinical trials that integrate both neuropsychiatric and gut health outcomes.
Abstract
Inflammatory Bowel Disease (IBD), comprising Crohn’s Disease and Ulcerative Colitis, is a chronic inflammatory condition of the gastrointestinal tract with a remarkably high prevalence of psychiatric comorbidities, particularly Major Depressive Disorder (MDD). The traditional monoaminergic hypothesis of depression is insufficient to explain the complex etiology of MDD, paving the way for new paradigms, such as the inflammatory hypothesis of depression. This narrative review critically explores IBD as a human clinical model to investigate the connection between chronic inflammation and depression. It is argued that gut dysbiosis, a central feature of IBD, is a fundamental trigger that, through a compromised gut barrier, drives systemic inflammation and, subsequently, neuroinflammation. We detail the molecular and cellular mechanisms that link intestinal inflammation to central nervous system (CNS) dysfunction, including microglial activation, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and kynurenine pathway activation, which diverts tryptophan metabolism from serotonin synthesis to the production of neurotoxic metabolites. Robust epidemiological evidence demonstrating a bidirectional association between IBD and depression is discussed, suggesting a shared pathophysiology rather than a simple cause-and-effect relationship. Furthermore, we review the implications and emerging therapeutics, highlighting the antidepressant effects of immunobiologicals, such as anti-TNF therapies, and the potential of emerging interventions that target the microbiome, such as probiotics, psychobiotics, fecal microbiota transplantation, and anti-inflammatory diets. Furthermore, we address the limitations of the current literature, such as the lack of a quantitative definition for dysbiosis and the scarcity of clinical trials with integrated neuropsychiatric outcomes, and propose directions for future translational research. We conclude that IBD should be considered a systemic disease with significant psychiatric repercussions, advocating for an integrated therapeutic approach that combines immunomodulatory, neuromodulatory, and microbiological interventions to treat both gut and brain pathology effectively.